EGFR: A best-in-class strategy study

In the first-in-class versus best-in-class debate, the story of EGFR inhibitors stands out not only as a case study in deriving value from best-in-class strategies, but as one that maps the course of biotech’s history, with new biology and innovative technologies enabling a field to continually progress with major, and not just incremental, advances. 

For more than two decades, small molecules, followed by mAbs and bispecific antibodies, have been gaining regulatory approvals to treat cancer patients harboring mutations in the EGFR receptor. ...